New hope for tough cancers: experimental drug TB511 enters human trials

This early-phase trial tests a new drug called TB511 in people with advanced solid tumors (lung, prostate, colorectal, or liver cancer) that have stopped responding to standard care. The study has two parts: first, finding the safest dose of TB511 alone; second, testing TB511 combined with the immunotherapy pembrolizumab. About 12 participants will be enrolled to check safety and whether the drug shrinks tumors.